Amin HAA, Kobaisi MH, Samir RM. Schistosomiasis and bladder cancer in Egypt: truths and myths. Open Access Maced J Med Sci. 2019;7(23):4023–9. https://doi.org/10.3889/oamjms.2019.857.

Article  PubMed  PubMed Central  Google Scholar 

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/jco.1995.13.1.8.

Article  CAS  PubMed  Google Scholar 

Ogihara K, Kikuchi E, Watanabe K, Kufukihara R, Yanai Y, Takamatsu K, et al. Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy? Oncotarget. 2017;8(67):111819–35. https://doi.org/10.18632/oncotarget.22911.

Article  PubMed  PubMed Central  Google Scholar 

Franzese C, Francolini G, Nicosia L, Alongi F, Livi L, Scorsetti M. Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies. Clin Oncol (R Coll Radiol). 2021;33(1):50–6. https://doi.org/10.1016/j.clon.2020.07.008.

Article  CAS  PubMed  Google Scholar 

Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, et al. Definition and diagnosis of oligometastatic bladder cancer: a Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023

Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J Urol. 2016;195(2):277–82. https://doi.org/10.1016/j.juro.2015.07.111.

Article  PubMed  Google Scholar 

Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5. https://doi.org/10.1200/jco.2009.25.4599.

Article  PubMed  Google Scholar 

Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, et al. Better survival of patients with oligo-compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021;10

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder cancer, Version 3.2020. NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2020;18(3):329–54. https://doi.org/10.6004/jnccn.2020.0011.

Article  PubMed  Google Scholar 

Pisters LL, Westney L. The management of locally recurrent invasive bladder cancer following radical cystectomy. Semin Urol Oncol. 1996;14(2):112–9.

CAS  PubMed  Google Scholar 

Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998;159(3):792–5.

Article  CAS  PubMed  Google Scholar 

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2023;41(22):3772–81.

Article  PubMed  Google Scholar 

Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012;109(6):846–54. https://doi.org/10.1111/j.1464-410X.2011.10455.x.

Article  PubMed  Google Scholar 

Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser Hr, Markwalder R, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21(4):690–6

Cagiannos I, Morash C. Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J. 2009;3(6 Suppl 4):S237–42. https://doi.org/10.5489/cuaj.1205.

Article  PubMed  PubMed Central  Google Scholar 

Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am. 2003;30(4):777–89. https://doi.org/10.1016/s0094-0143(03)00061-2.

Article  PubMed  Google Scholar 

Zehnder P, Studer UE, Skinner EC, Thalmann GN, Miranda G, Roth B, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 2013;112(2):E51–8. https://doi.org/10.1111/bju.12215.

Article  PubMed  Google Scholar 

Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, et al. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol. 2020;50(2):206–13. https://doi.org/10.1093/jjco/hyz152.

Article  PubMed  Google Scholar 

Faltas BM, Gennarelli RL, Elkin E, Nguyen DP, Hu J, Tagawa ST. Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes. Urol Oncol. 2018;36(1):9.e11-9.e7. https://doi.org/10.1016/j.urolonc.2017.09.009.

Article  PubMed  Google Scholar 

Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M D Anderson experience. J Urol. 2004;171(1):145–8. https://doi.org/10.1097/01.ju.0000099823.60465.e6.

Article  PubMed  Google Scholar 

Iwamoto H, Izumi K, Shimura Y, Natsagdorj A, Maolake A, Takezawa Y, et al. Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res. 2016;36(10):5557–61. https://doi.org/10.21873/anticanres.11140.

Article  CAS  PubMed  Google Scholar 

Muilwijk T, Akand M, Van der Aa F, Dumez H, De Meerleer G, Van Raemdonck D, et al. Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Transl Androl Urol. 2020;9(3):1296–305. https://doi.org/10.21037/tau-19-624.

Article  PubMed  PubMed Central  Google Scholar 

Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49. https://doi.org/10.1016/s0022-5223(97)70397-0.

Article  CAS  PubMed  Google Scholar 

Zaghloul MS. Adjuvant and neoadjuvant radiotherapy for bladder cancer: revisited. Future Oncol. 2010;6(7):1177–91. https://doi.org/10.2217/fon.10.82.

Article  PubMed  Google Scholar 

Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98–106. https://doi.org/10.1016/s1470-2045(20)30537-4.

Article  PubMed  Google Scholar 

Aboudaram A, Chaltiel L, Pouessel D, Graff-Cailleaud P, Benziane-Ouaritini N, Sargos P, et al. Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis. Cancers (Basel). 2023. 15(4). https://doi.org/10.3390/cancers15041161. This recent article is the largest retrospective study on radiotherapy for oligometastatic urothelial cancer, consisting of 91 patients from four comprehensive cancer centers from 2005 to 2018, which demonstrated a large overall (HR 0.47) and progression free (HR 0.49) survival benefit.

Francolini G, Desideri I, Detti B, Di Cataldo V, Masi L, Caramia G, et al. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience. Cancer Treat Res Commun. 2019;19:100124. https://doi.org/10.1016/j.ctarc.2019.100124.

Article  CAS  PubMed  Google Scholar 

Augugliaro M, Marvaso G, Ciardo D, Zerini D, Riva G, Rondi E, et al. Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy? Neoplasma. 2019;66(1):160–5. https://doi.org/10.4149/neo_2018_180522N333.

Article  CAS  PubMed  Google Scholar 

Nevens D, Jongen A, Kindts I, Billiet C, Deseyne P, Joye I, et al. Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature. Int J Radiat Oncol Biol Phys. 2022;114(4):587–95. https://doi.org/10.1016/j.ijrobp.2022.06.067.

Article  PubMed  Google Scholar 

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.

Article  CAS  PubMed  Google Scholar 

Leonetti A, D’Abbiero N, Baldari G, Andreani S, Ruffini L, Viansone AA, et al. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series. Int J Urol. 2018;25(10):879–86. https://doi.org/10.1111/iju.13773.

Article  PubMed  Google Scholar 

Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023;34:S1340. https://doi.org/10.1016/j.annonc.2023.10.106.

Article  Google Scholar 

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778–89. https://doi.org/10.1056/NEJMoa2309863.

Article  PubMed  Google Scholar 

Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere WR, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9. https://doi.org/10.1200/jco.2004.11.024.

Article  PubMed  Google Scholar 

Fischer-Valuck BW, Michalski JM, Mitra N, Christodouleas JP, DeWees TA, Kim E, et al. Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Med. 2019;8(8):3698–709. https://doi.org/10.1002/cam4.2102.

Article  PubMed  PubMed Central  Google Scholar 

Wishnow KI, Dmochowski R. Pelvic recurrence after radical cystectomy without preoperative radiation. J Urol. 1988;140(1):42–3. https://doi.org/10.1016/s0022-5347(17)41480-7.

Article  CAS  PubMed  Google Scholar 

Ballas L, Wei O, Daneshmand S, Schuckman A, Djaladat H, Aron M, et al (2020) Chemoradiation for management of locally recurrent or residual bladder cancer: a case series and review of the literature Clin Genitourin Cancer 18 4 e473-e7. https://doi.org/10.1016/j.clgc.2019.12.016. This recent article involving a case series of five patients with locally recurrent urothelial cancer is the first to demonstrate the potential safety and efficacy of locoregional chemoradiation treatment in this setting.